Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$72.54 - $95.56 $1,160 - $1,528
-16 Reduced 94.12%
1 $136,000
Q4 2023

Jun 26, 2024

BUY
$61.71 - $77.76 $61 - $77
1 Added 100.0%
2 $186,000
Q3 2023

Nov 15, 2023

SELL
$69.28 - $93.38 $5,334 - $7,190
-77 Reduced 81.91%
17 $1,000
Q2 2023

Aug 08, 2023

BUY
$81.41 - $94.33 $895 - $1,037
11 Added 13.25%
94 $224,000
Q1 2023

May 12, 2023

BUY
$74.26 - $84.51 $6,163 - $7,014
83 New
83 $202,000
Q3 2022

Nov 03, 2022

SELL
$82.37 - $107.29 $2,965 - $3,862
-36 Reduced 12.63%
249 $202,000
Q2 2022

Aug 05, 2022

SELL
$86.5 - $128.27 $5,968 - $8,850
-69 Reduced 19.49%
285 $233,000
Q1 2022

May 13, 2022

SELL
$101.96 - $128.34 $3,670 - $4,620
-36 Reduced 9.23%
354 $288,000
Q4 2021

Feb 11, 2022

BUY
$106.37 - $130.68 $41,271 - $50,703
388 Added 19400.0%
390 $317,000
Q3 2021

Nov 12, 2021

BUY
$102.91 - $122.75 $205 - $245
2 New
2 $113,000
Q2 2021

Aug 11, 2021

SELL
$83.84 - $104.76 $167 - $209
-2 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$78.68 - $90.67 $157 - $181
-2 Reduced 50.0%
2 $205,000
Q4 2020

Feb 16, 2021

BUY
$71.69 - $91.23 $286 - $364
4 New
4 $0
Q2 2020

Aug 13, 2020

SELL
$57.54 - $76.95 $287 - $384
-5 Closed
0 $0
Q1 2020

May 12, 2020

SELL
$52.41 - $81.0 $5,241 - $8,100
-100 Reduced 95.24%
5 $0
Q3 2019

Oct 15, 2019

BUY
$61.55 - $75.43 $4,924 - $6,034
80 Added 320.0%
105 $23,000
Q2 2019

Jul 26, 2019

SELL
$55.74 - $64.41 $167 - $193
-3 Reduced 10.71%
25 $5,000
Q1 2019

Apr 19, 2019

SELL
$47.89 - $64.05 $16,713 - $22,353
-349 Reduced 92.57%
28 $5,000
Q3 2018

Oct 31, 2018

BUY
$45.7 - $58.03 $14,075 - $17,873
308 Added 446.38%
377 $52,000
Q2 2018

Aug 14, 2018

SELL
$42.45 - $51.3 $806 - $974
-19 Reduced 21.59%
69 $9,000
Q1 2018

May 23, 2018

BUY
$37.19 - $47.45 $3,272 - $4,175
88 New
88 $12,000

Others Institutions Holding EW

About Edwards Lifesciences Corp


  • Ticker EW
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 618,259,968
  • Market Cap $41.9B
  • Description
  • Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair...
More about EW
Track This Portfolio

Track Financial Gravity Asset Management, Inc. Portfolio

Follow Financial Gravity Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.